Liver Disease Diagnostics Market Report 2026

The liver disease diagnostics market size has grown strongly in recent years. It will grow from $38.95 billion in 2025 to $41.84 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing prevalence of hepatitis infections, rising alcohol consumption patterns, early reliance on blood-based liver tests, growing incidence of liver cirrhosis, expansion of hospital diagnostic infrastructure.

The liver disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $55.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising burden of NAFLD and NASH, growing awareness of preventive liver care, increasing adoption of advanced imaging techniques, expansion of population health screening programs, higher healthcare spending on diagnostics. Major trends in the forecast period include growing demand for early liver disease detection, rising use of non-invasive diagnostic techniques, increasing screening for fatty liver and fibrosis, expansion of routine liver function testing, rising clinical focus on disease progression monitoring.

The rise in alcohol consumption is anticipated to drive the growth of the liver disease diagnostics market in the coming years. Alcohol intake is increasing due to factors such as shifting social norms, improved affordability, easy availability, and growing stress or mental health issues. Liver disease diagnostics play a vital role in monitoring the effects of alcohol consumption on liver health, aiding in the early detection of liver damage such as fatty liver, hepatitis, or cirrhosis. For example, in December 2024, according to the Bureau of Labor Statistics, a U.S.-based government agency, U.S. households spent an average of $294 on alcoholic beverages consumed at home and $343 on those consumed outside the home in 2023. Consequently, the rise in alcohol consumption is fueling the growth of the liver disease diagnostics market.

Major companies operating in the liver disease diagnostics market are concentrating on developing innovative solutions, such as non-invasive tools for liver evaluation, to create more precise and efficient diagnostic methods. A non-invasive tool for liver assessment refers to diagnostic techniques that examine liver conditions using methods like elastography or blood tests, eliminating the need for invasive procedures like biopsies. For example, in September 2024, City Imaging & Clinical, an India-based diagnostic center, introduced FibroScan, a non-invasive diagnostic tool for liver evaluation, targeting the early detection of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). This advanced technology enables rapid and accurate measurement of liver stiffness and fat content without requiring invasive procedures like biopsies. The process is quick, usually taking 5 to 15 minutes, and involves placing a probe on the skin over the liver. The probe emits sound waves that measure liver tissue stiffness, aiding in the assessment of fibrosis or scarring.

In August 2024, Quest Diagnostics, a US-based medical laboratory company, acquired LifeLabs for $1 billion. This acquisition is expected to help Quest Diagnostics considerably strengthen its operational capabilities, financial performance, and competitive position within the North American healthcare market. LifeLabs is a Canada-based laboratory company that provides liver disease diagnostics, with a particular focus on non-alcoholic fatty liver disease (NAFLD).

Major companies operating in the liver disease diagnostics market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Fujifilm Holdings Corporation, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, bioMérieux SA, Echosens SA, Hologic Inc., Canon Medical Systems Corporation, GE HealthCare Technologies Inc., Mindray Bio-Medical Electronics Co. Ltd., Samsung Medison Co. Ltd., Bruker Corporation, Sysmex Corporation, DiaSorin S.p.A., Perspectum Diagnostics Ltd., Owlstone Medical Ltd., HEPQuant LLC, Aiforia Technologies Plc.

North America was the largest region in the liver disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liver disease diagnostics market by increasing costs associated with imported imaging systems, diagnostic reagents, and laboratory consumables. These impacts are more pronounced across imaging and laboratory testing segments, particularly in regions such as asia-pacific and europe that rely on cross-border medical equipment supply chains. Hospitals and diagnostic laboratories face higher procurement and operational costs due to tariff pressures. However, tariffs have also encouraged local manufacturing of diagnostic kits, regional sourcing of consumables, and strengthened domestic diagnostic capabilities, supporting long-term market resilience.

The liver disease diagnostics market research report is one of a series of new reports that provides liver disease diagnostics market statistics, including liver disease diagnostics industry global market size, regional shares, competitors with a liver disease diagnostics market share, detailed liver disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver disease diagnostics industry. This liver disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver disease diagnostics involve medical procedures and tests used to detect and evaluate various liver conditions, such as liver cirrhosis, hepatitis, fatty liver disease, and liver cancer. These diagnostic approaches typically include blood tests to measure liver enzyme levels, imaging methods like ultrasound or CT scans, and sometimes biopsy procedures to collect tissue samples.

The primary diagnostic methods in liver disease diagnostics include laboratory tests, imaging, endoscopy, biopsy, and other diagnostic approaches. Laboratory tests focus on analyzing blood and other samples to identify liver diseases. They are applied to conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and other liver disorders, serving various end users, including hospitals, laboratories, and others.

The liver disease diagnostics market consists of revenues earned by entities by providing services such as liver disease diagnostics, imaging studies, fibrosis assessment, viral hepatitis screening, and alcohol-related liver disease evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver disease diagnostics market also includes sales of blood test kits, imaging devices, and biopsy needles and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.